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Background:  Detailed  cost  evaluations  of delivery  of  new  vaccines  such  as  pneumococcal  conjugate,
human  papillomavirus  (HPV),  and  rotavirus  vaccines  in  low  and  middle-income  countries  are  scarce.
This  paper  differs  from  others  by comparing  the  costs  of  introducing  multiple  vaccines  in a single  coun-
try  and  then  assessing  the  ﬁnancial  and economic  impact  at the time  and  implications  for  the  future.  The
objective  of  the  analysis  was  to  understand  the  introduction  and  delivery  cost  per dose  or  per  child  of
the  three  new  vaccines  in Rwanda  to inform  domestic  and  external  ﬁnancial  resource  mobilization.
Methods:  Start-up,  recurrent,  and  capital  costs  from  a government  perspective  were collected  in 2012.
Since  pneumococcal  conjugate  and  HPV  vaccines  had  already  been  introduced,  cost  data  for  those  vaccines
were collected  retrospectively  while  prospective  (projected)  costing  was  done  for  rotavirus  vaccine.
Results:  The  ﬁnancial  unit  cost  per fully  immunized  child  (or  girl  for  HPV  vaccine)  of  delivering  3  doses
of  each  vaccine  (without  costs  related  to vaccine  procurement)  was  $0.37  for rotavirus  (RotaTeq®)  vac-
cine, $0.54  for pneumococcal  (Prevnar®) vaccine  in  pre-ﬁlled  syringes,  and  $10.23  for HPV  (Gardasil ®)
vaccine.  The  ﬁnancial  delivery  costs  of  Prevnar® and  RotaTeq® were  similar  since  both  were  delivered
using  existing  health  system  infrastructure  to  deliver  infant vaccines  at health  centers.  The  total  ﬁnancial
cost  of delivering  Gardasil® was  higher  than  those  of the  two  infant  vaccines  due  to greater  resource
requirements  associated  with  creating  a new  vaccine  delivery  system  in  for a new  target  population
of  12-year-old  girls  who  have not  previously  been  served  by  the  existing  routine  infant  immunization
program.
Conclusion:  The  analysis  indicates  that  service  delivery  strategies  have  an  important  inﬂuence  on  costs
of introducing  new  vaccines  and  costs  per  girl reached  with  HPV  vaccine  are  higher  than  the  other
two  vaccines  because  of  its delivery  strategy.  Documented  information  on  ﬁnancial  commitments  for
new  vaccines,  particularly  from government  sources,  is  a useful  input  into  country  policy  dialogue  on
sustainable  ﬁnancing  and  co-ﬁnancing  of new  vaccines,  as  well  as  for  policy  decisions  by  donors  such  as
Gavi, the Vaccine  Alliance.
©  2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author. Tel.: +41 79 79 39 582.
E-mail address: hutubessyr@who.int (R. Hutubessy).
1 Independent consultant.
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.022
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).1. IntroductionOnly a few detailed cost evaluations of the delivery of new vac-
cines such as pneumococcal, human papillomavirus (HPV), and
rotavirus vaccines in low and middle-income countries exist [1–5].
This paper differs from other papers since it evaluates not only
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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Table 1
Description of vaccination activities in cost analysis.
Description
Micro-planning Meetings at national and district level for
planning vaccine introduction activities
Training Development of training curricula and
materials, Training of trainers, training of
supervisors, training of vaccinators at
district/provincial level, training of monitors
Social Mobilization and
Information,
Education, and
Communication (IEC)
Meetings with community leaders, IEC
material development, production of leaﬂets,
posters, TV spots, and radio, media/journalist
workshop
Vaccine/injection
supply procurement
Procurement of vaccines and injection
supplies, clearance from customs, receiving,
storage, and co-ﬁnancing fees for Gavi
supported vaccines
Service delivery Personnel time spent on vaccination and
traveling, per diem and transport costs
associated with health worker vaccination of
infants or adolescent girls.
Supervision,
monitoring &
evaluation
Supervisory trips by national and district-level
program managers, production of registers and
tally sheets, disease surveillance, and
post-introduction evaluation
Waste management Incineration and burial of syringes, safety
boxes and vaccine containers358 F. Ngabo et al. / Vacc
he costs of introducing individual vaccines, but also the costs of
ntroducing multiple vaccines in a single country and then assesses
he ﬁnancial and economic impact at the time and implications for
he future.
The policy implications of having accurate cost and ﬁnancing
nformation are several. These data can be used to improve plan-
ing of resource requirements and ﬁnancing needs for multiple
accine introductions at country level to evaluate their affordabil-
ty. Understanding the delivery cost per dose or per child of new
accines is important for informing domestic and external resource
obilization. Documented information on ﬁnancial commitments
or new vaccines, particularly from government sources, is a useful
nput into country policy dialogue on sustainable ﬁnancing and co-
nancing of new vaccines, as well as for policy decisions by donors
uch as Gavi the Vaccine Alliance.
Rwanda is a small landlocked country with a population of
0.6 million located in East Africa. The Government of Rwanda
GOR) has had many achievements in health sector reform includ-
ng the introduction of a system of performance-based ﬁnancing
nd community-health insurance that covers more than 90 per-
ent of the population with minimal co-payment. Rwanda has been
ery successful in achieving mortality reduction. Between 2005 and
010, its child mortality decreased from 152 to 76 per 1000 live
irths and its infant mortality from 86 to 50 [6].
Rwanda was the ﬁrst African country with national immuniza-
ion programme introductions of pneumococcal conjugate vaccine
Prevnar®) in 2009, HPV vaccine (Gardasil®) in 2011 and rotavirus
accine (RotaTeq®) in 2012. Prevnar® was initially provided in 2009
hrough Gavi via a donation from the manufacturer, Wyeth, and
as then supported by Gavi with country co-ﬁnancing beginning
n 2010. 2 Gardasil® was provided through a three-year donation
rom the manufacturer, Merck, during 2011–2013 [7], and was
upported by GAVI with country co-ﬁnancing starting in 2014.
otateq® was introduced in 2012 through Gavi support with coun-
ry co-ﬁnancing.
All three vaccines had the similar requirement of having 3-dose
chedules for administration but the vaccine products differed in
ther aspects. The vaccine product presentations were different
nd this had consequences on the cold chain volume and waste
anagement: Prevnar® was in a preﬁlled syringe for intramus-
ular injection (cold chain volume: 55.9 cm3); RotaTeq® was in
 single dose tube for oral administration (cold chain volume:
6.3 cm3); and Gardasil® was in a single dose vial (cold chain vol-
me: 15 cm3) with separate syringe for intramuscular injection.
urthermore, target populations and delivery strategies for the
hree vaccines differed. Pneumococcal and rotavirus vaccines are
ecommended for infants and are commonly given through immu-
ization sessions using the existing health system and existing
ealth service delivery structure. The recommended target pop-
lation for HPV vaccine is 9–13 year old girls [8], a population that
as not been routinely served by immunization programs in most
ow or low middle income countries. Thus, the decision to intro-
uce HPV vaccine in such countries requires creation of new vaccine
elivery services in order to deliver multiple doses to each girl. In
wanda, all three doses of HPV vaccine were delivered at schools
o girls in primary grade 6 and were delivered at health facili-
ies to a smaller proportion of girls (3%) who were not attending
chool.
The objective of the analysis was to estimate the cost of
ntroducing and delivering each of the three vaccines nationwide
n Rwanda, a low-income country, and to compare and understand
2 Rwanda switched its presentation of Prevnar® from preﬁlled syringe to vials
PCV13) when it switched to GAVI ﬁnancing.Cold chain Purchase of additional cold chain equipment to
store and transport vaccines
the differences in cost components among the different vaccines to
identify the main cost drivers.
2. Methods
The analysis focused on estimating the incremental direct costs
to the government health system of vaccinating children with the
new vaccines and did not include existing costs of buildings or
cold chain infrastructure. No indirect costs such as cost to the user
(children, parents or caregivers) due to productivity losses were
included.
The cost components for service delivery included startup
costs (micro-planning, training, social mobilization and Informa-
tion, Education, and Communication (IEC)), recurrent (vaccine and
injection supply procurement, service delivery, supervision and
monitoring and evaluation, and waste management) and capital
costs (purchase of cold chain equipment). See Table 1 for a descrip-
tion of vaccination activities.
Both ﬁnancial (or costs to the MoH) and economic costs were
estimated so that opportunity costs could be compared. Financial
costs included the value of resources purchased (or real expendi-
tures) for the vaccine introduction. For example, these included
resources used for vaccination (vaccines and injection supplies),
training, social mobilization, transport and outreach allowances.
Financial costs differ from economic costs since ﬁnancial costs do
not include resources that are already paid for or owned by the
MoH  such as the salaries of health personnel or resources paid for
by external partners such as vaccines.
Table 2 provides an overview of the different cost components
for calculating ﬁnancial and economic costs. Service delivery is
comprised of personnel, per diem and travel. However, salaries for
personnel are already paid for by the Rwanda government, there-
fore, ﬁnancial costs consist of per diem and travel allowances for
personnel. These costs were only incurred for Gardasil since 97% of
vaccines were delivered at schools, where health workers, commu-
nity health workers and supervisors received per diem and travel
allowance for the school based vaccination program. Rotateq and
Prevnar were provided at health facilities.
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Table  2
Cost components by vaccine service delivery category.
Financial Economic
Startup
Micro-planning • Room rental
• Refreshments
Financial costs plus the following:
• Value of health worker time
Training • Training materials
• Supplies
• Venue rental
• Facilitator fees
Per diems
• Travel allowances
Financial costs plus the following:
• Value of health worker time
• For Gardasil also teacher or headmaster time
Social  Mobilization/Information,
Education, and Communication
(IEC)
• IEC materials
• Printing
• Airing radio/TV spots
•  Venue rental
• Material development meetings
Financial costs plus the following:
• Value of health worker time
• For Gardasil also teacher or headmaster time
Recurrent
Service  delivery • Health worker per diems
• Travel allowances
• Fuel and maintenance
Financial costs plus the following:
• Value of health worker time
Vaccine procurement • For Prevnar and RotaTeq, there were Gavi co-ﬁnancing
costs but no costs related to receiving, customs clearance,
or storage
• For Gardasil which was  a manufacturer’s donation, no
Gavi co-ﬁnancing costs, but costs of syringes, receiving,
customs clearance, and storage
Financial costs plus the following:
• Cost of vaccines (less co-ﬁnancing)
M&E,  Supervision • Fuel, per diem and travel allowances for supervisory trip
•  Printing new vaccination cards and tally sheets
Post-introduction evaluation
• Surveillance
Financial costs plus the following:
• Value of supervisor time
Waste  management • Cost of waste disposal Cost of waste disposal
Capital
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at the district and health facility level, these were not included due
to lack of information. Thus, the total cost of delivering the vaccines
was slightly underestimated.Cold  chain equipment 
Since vaccines were donated by Merck or obtained at subsidized
rices by GAVI, the ﬁnancial costs for vaccines included govern-
ent co-pays to Gavi for Prevnar and RotaTeq, as well as ﬁnancial
utlays for receiving and storing vaccines at the airport and syringes
or Gardasil. The government co-pays for Prevnar® or Rotateq® of
0.20 per dose were included as well as the cost of receiving and
toring Gardasil®. Vaccine costs were not included as part of ﬁnan-
ial costs except for government co-pays to Gavi for Prevnar® and
otaTeq® since these commodities were donated; however, the
overnment paid for receiving and storing the vaccines at the air-
ort as well as to purchase syringes for Gardasil®. Service delivery
nancial costs (deﬁned as per diem and travel allowances paid to
ealth workers and supervisors and deﬁned in Table 3) were only
ncurred for Gardasil® since 97% of this vaccine was  provided at
chools in Rwanda whereas the other two vaccines are provided at
ealth facilities.
All three of the vaccines had three dose schedules but each had
ifferent sources of ﬁnancing and prices per dose. Prevnar® was
upported by Gavi through an Advance Market Commitment [11]
nd the price per dose was subsidized at $3.50 through this mecha-
ism. Gardasil® was provided through a three-year donation from
erck and the country paid for syringes and receiving and storing
he vaccine. We  assumed that the price per dose of Gardasil® and
otaTeq® would be $5.003 per dose to the manufacturer and Gavi,
espectively, for the economic costs.
The value of personnel time was included in the economic cost
stimate. The time cost is estimated through multiplying the salary
er minute by the number of minutes required for a vaccination.
dditional outreach allowances are added for Gardasil vaccination
ince these activities took place outside of the health facilities.
3 The assumption was  made before GAVI negotiated a price of $4.50 for Gardasil
ith the manufacturer.Divided cold chain equipment purchase in 2007 between
Prevnar and Gardasil. New refrigerators were purchased in
2011 for Rotateq.
The cost of additional cold chain equipment was  depreciated4
for each of the three vaccines. New cold chain equipment was
purchased twice in preparation for the introduction of the three
vaccines. The cost of new equipment was  divided among the new
vaccines.5
The ﬁnancial and economic costs of all the resources used for
vaccination were totaled and shown with and without the esti-
mated cost of the vaccine so that service delivery costs could be
analyzed. The total cost was  also divided by the number of doses
administered and number of fully immunized children (FIC) or girls
(FIG) to estimate the cost per dose and cost per FIC/FIG. The year
of analysis for each vaccine is the ﬁrst full year for which the vac-
cine was introduced. Ofﬁcial exchange rates of the Rwandan Franc
against the US dollar were used according to the year of actual
or planned vaccine introduction (2010, 2011, or 2012) and were
580, 600 and 610 Rwandan francs per US dollar, respectively, and
according to the Rwanda National Bank [12–14]. The reporting year
is 2012 US$.
Since this analysis evaluated incremental costs, no shared health
systems costs across the vaccines for sub-national vaccine supply
chain logistics were included. Even though it was likely that some
service delivery costs such as transport were likely to be incurred4 The assumption for useful life years for cold chain equipment was 10 years for
refrigerators with a discount rate of 3%.
5 During the ﬁrst cold chain expansion, new equipment were purchased in
preparation for the introductions of Prevnar® and Rotateq® . After the Rotateq®
introduction was delayed, the equipment purchased for this vaccine was instead
used for the Gardasil® introduction. During the analysis, we divided the cost of the
initial cold chain equipment between Prevnar® and Gardasil® and allocated the cost
of  the second set of equipment to Rotateq® .
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Table  3
Assumptions made for delivery cost analysis of vaccines.
Vaccine Prevnar® Rotateq® Gardasil®
Target population 376,202 infants 0-1 years in 2010 394,473 infants 0-1 years in 2012 91,317 girls in P6 in school (9-18
years) and 3,066 girls who were
out of school and 12 years old
Number of doses per child 3 3 3
Price  of Vaccine Financial: $0.20 per dose
co-ﬁnancing
Economic: $3.50/dose
Financial: $0.20 per dose
co-ﬁnancing
Economic: $5.00/dose
Vaccines donated during 1st three
years but MoH  paid for syringes,
receiving, clearance and storage;
assumed $5.00/dose for economic
costs (not inclusive of costs of
receiving and storage of the
vaccine)
Type  of Vaccine,
presentation and cold
chain volume
Prevnar® in preﬁlled syringe for
intramuscular injection, 55.9 cc
RotaTeq® in single dose applicator
for oral administration, 46.3 cc
Gardasil® in single dose vial with
separate syringe for intramuscular
injection, 15 cc.
Administrative Vaccine
Coverage
First dose coverage was reported to
be 80%, then dropout of
approximately 1% occurred for
each of the 2nd and 3rd doses
Assume 80% coverage for 1st dose,
with 1% and 0.5% dropout rates for
2nd and 3rd doses
First dose was reported to be 97%
with dropout of 2% occurred for
each of the 2nd and 3rd doses
Country Co-ﬁnancing for
Gavi
Rwanda began co-ﬁnancing
Prevnar®a in 2010 at $0.20/dose
Co-ﬁnancing will begin in 2012 at
$0.20/dose
NA
Introduction Costs
(Micro-planning,
training, Soc.Mob./IEC)
Assumed to last ﬁve years Assumed to last ﬁve years Assumed to last ﬁve years
Cold  Chain bHalf of the cold chain equipment
purchased for Prevnar was  later
used for HPV vaccines
New refrigerators were purchased
for Rotateq® .for the district (87)
and health center levels (131).
bHalf of the cold chain equipment
purchased for Prevnar was later
used for HPV vaccines
Service delivery Six minutesc vaccinator time per
vaccination in clinic
Six minutes vaccinator time per
vaccination in clinic
Six minutesc vaccinator time per
vaccination in clinic Health worker
outreach allowances (5000
Rwanda francs or approximately
$8) for visiting each school; 2,510
schools were visited by teams of 2
health workers
Supervision Supervisory trips three times a
year: Travel allowance, per diem,
fuel; staff salaries; 20% allocated to
PCV
Supervisory trips three times a
year: Travel allowance, per diem,
fuel; staff salaries; 20% allocated to
RV
Supervision takes place during HPV
vaccination and included in cost of
service delivery
Monitoring and evaluation Printing of new vaccination cards
and tally sheets, post-introduction
evaluation, surveillance
Printing new vaccination cards,
post-introduction evaluation,
surveillance
Printing new vaccination cards,
post-introduction evaluation,
surveillance
Waste management Incineration and Burial of preﬁlled
syringes;
Incineration and Burial; Disposal of
plastic dosing tubes
Incineration and Burial
a Rwanda obtained Prevnar as a donation from Wyeth, the manufacturer, in 2009 and the government only paid for transport, receiving and clearance; it began getting
the  vaccine through Gavi in 2010 and paying the co-ﬁnancing fees.
b ribute
m
c
a
f
f
2
R
a
p
v
C
d
v
t
p
a
dSince 50% of the cold chain costs for the Prevnar introduction were actually att
ated.
c Based on program manager estimates.
Table 3 shows assumptions that were made in the analysis of
osts to introduce the vaccines. The assumptions for vaccine cover-
ge were based on the administrative coverage reported by Rwanda
or Prevnar® and Gardasil®. We  assumed that the same coverage
or RotaTeq® would be achieved as for Prevnar.
.1. Data collection
During January until May  2012, the study team, comprised of a
wandan economist (CK), an international health economist (AL),
nd the Rwandan immunization program manager (MG), collected
rimary and secondary data on the costs of introducing the 3
accines using the WHO  Cervical Cancer Prevention and Control
osting Tool (C4P) [9].
The WHO  C4P Tool that was used for analysis was  initially
eveloped for estimating the cost of planned introduction of HPV
accines in the United Republic of Tanzania [14]. The WHO  C4P
ool is an Excel based tool that enables the user to estimate and
roject the value of incremental (additional) resources required
t national, provincial and district level to add the country-wide
elivery of HPV vaccine to an existing immunization program overd to Gardasil introduction, the costs of introducing Prevnar was  slightly underesti-
a ﬁve-year period. It uses a mixture of ingredients and expenditure
approach to costing.
The WHO  C4P tool was used to guide data collection and entry
for the Gardasil HPV vaccine against cervical cancer. The tool
was modiﬁed to estimate retrospective costs for Prevnar® and
Gardasil®, as well as modiﬁed to estimate prospective (projected)
costs of introducing Rotateq®. As Prevnar® and Gardasil® vaccines
had already been introduced into the country at the time of this cost
assessment, the cost analyses for those two  vaccines were retro-
spective while for RotaTeq®, the estimated resource requirements
of vaccination were projected.
Table 4 shows the data sources for the study. The study team col-
lected data related to vaccine delivery on target populations, health
facilities, schools, and costs and quantities of required resources
from the national immunization program, Ministry of Education,
the Ministry of Health (MoH), and the Rwandan Comprehensive
Multi-Year Plan (cMYP) [10]. The team also interviewed immu-
nization program managers and other partners (WHO, UNICEF, and
USAID) to obtain information on programmatic options, cold chain
equipment purchases and other cost data. They also collected data
on facility and outreach costs from visits to a small sample of two
health centers and one hospital. Note that since no data on waste
F. Ngabo et al. / Vaccine 33 (2015) 7357–7363 7361
Table  4
Data sources for cost study.
Data Sources Type of data
Micro-planning,
training, social
mobilization/IEC,
service delivery,
waste management
Rwandan National
Immunization
Program, WHO
Primary/secondary
Number of health
facilities
Rwandan Ministry of
Health
Secondary
Number of girls
enrolled in Primary 6
grade, number of
schools
Rwandan Ministry of
Education
Primary/secondary
Population size of
infants and girls
Rwandan Bureau of
Statistics
Primary/secondary
Health worker salaries Rwandan
comprehensive
multi-year plan (cMYP)
Secondary
Cold chain UNICEF, USAID, and Secondary
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Table 5
Total ﬁnancial and economic costs of three vaccine introductions in Rwanda in 2012
US$.
Prevnar RotaTeq Gardasil
Target number of children
to be vaccinated
376,202 394,473 91,317
Financial costs
Startup
Micro-planning $4612 $4607 $13,197
Training $23,959 $12,231 $44,283
Social Mobiliza-
tion/Information,
Education, and
Communication
(IEC)
$30,170 $30,170 $53,125
Sub-total $58,741 $47,008 $110,605
Recurrent
Service delivery – – $735,009
Vaccines/injection
supplies
procurement
$565,366 $673,207 $156,503
Monitoring &
evaluation (M&E),
Supervision
$55,767 $61,902 $59,873
Waste management $46,253 $4694 $36,139
Sub-total $667,386 $739,803 $987,524
Capital: cold chain – – –
Total $726,127 $786,812 $1,098,129
Economic costs
Startup
Micro-planning $59,543 $56,151 $84,146
Training $111,412 $52,293 $107,628
Social Mobilization/IEC $34,885 $34,885 $79,745
Sub-total $205,840 $178,214 $271,519
Recurrent
Service delivery $243,662 $239,557 $904,918
Vaccines/injection
supplies
procurement
$4,471,911 $6,548,471 $1,951,594
M&E, Supervision $83,541 $83,324 $82,057
Waste management $59,161 $5,164 $48,672
Sub-total $4,858,275 $6,876,516 $2,987,241
Capital: cold chain $23,645 $32,895 $22,969
Total $5,087,760 $7,052,538 $3,281,720expenditures Gavi
anagement were available, the assumption was made that waste
isposal cost $0.10 per vaccination.
. Results of cost estimation of delivering Prevnar®,
otaTeq®, and Gardasil® Vaccines
Table 5 shows the total ﬁnancial and economic costs of introduc-
ng and delivering the three vaccines, adjusted to 2012 US$ and the
nit costs per dose of vaccine are found in Appendix 1. It should
e noted that the total costs of introducing Prevnar® and RotaTeq®
ere affected by differences in the size of the birth cohort in 2010
nd 2012 (376,202 and 394,473 infants, respectively).
.1. Financial Costs
Total ﬁnancial delivery costs were lowest for Prevnar® with an
nnual cost of $726,127. Costs were slightly higher for RotaTeq®
10%) and signiﬁcantly higher for Gardasil® (51%). The largest
ost component for Prevnar® and RotaTeq® was the vaccine co-
nancing, followed by monitoring and evaluation and supervision
hile the largest cost component for Gardasil® was service delivery
ue to the outreach allowances.
When startup costs were compared across vaccines, some
ariation was found. Training costs6 were lower for RotaTeq® intro-
uction than the other two vaccines since its training activities
ere combined with a larger training activity for multiple vac-
ines while Gardasil® vaccine introduction costs were higher due to
reater social mobilization and training requirements. The substan-
ial need for social mobilization and training was because the HPV
accine was targeted to an older (non-infant) age group and only
o girls and because vaccine delivery was primarily taking place
n schools and school staff, in addition to health workers, required
ome training on the vaccine.
Recurrent costs were greater for Gardasil® than for the other
wo vaccines. The costs of introducing HPV vaccine were approx-
mately 50% higher due to the additional service delivery costs of
elivering the vaccine to a new target population in the absence of
xisting social mobilization and service delivery infrastructure for
his population – in this case, vaccine delivery in schools. Recurrent
osts were slightly higher for RotaTeq® than Prevnar® due to the
arger infant target population in the introduction year (2012) than
6 Training costs were projected based on plans speciﬁed by the immunization
rogram manager.in the Prevnar® introduction year (2009/10). Waste management
costs were lower for RotaTeq® since it was  given orally and did not
require disposal of syringes.
The unit costs of introducing the three vaccines are shown in
Table 6 adjusted to 2012 US$. The ﬁnancial unit FIC/FIG cost of deliv-
ering the 3 vaccines (without vaccine procurement costs) ranged
from $0.37 for RotaTeq® to $10.23 for Gardasil® vaccine. The ﬁnan-
cial costs of Prevnar® and RotaTeq® vaccines were similar since
both were delivered using existing health system infrastructure
to deliver infant vaccines at health centers. The unit cost of deliv-
ering Gardasil® was higher than those of the two infant vaccines
due to greater resource requirements associated with creating new
vaccine delivery infrastructure to deliver vaccine to a new target
population of 12 year old girls.
3.2. Economic costs
The largest share of economic costs was  vaccine procurement
for all three vaccines. When economic costs were compared for
the three vaccines, the total annual costs were lower for Gardasil®
vaccine than for the other two vaccines due to lower procure-
ment costs – i.e., total procurement costs for Gardasil® were lower
since its target population number of adolescent girls in Primary 6
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Table  6
Financial and Economic Cost per Dose and Fully Immunized Child (FIC)/Fully Immu-
nized Girl (FIG) of Introducing Three New Vaccines in Rwanda 2012US$.
Prevnar in
Syringe and
Gavi Support
RotaTeq
Vaccine with
Gavi Support
Gardasil as
Manufacturer
Donation (no
co-pay)
Financial costs
Cost per dose (vaccine
procurement
costs + delivery costs)
$0.85
$0.84 $3.93
Delivery cost per dose
(no vaccine
procurement costs)
$0.18 $0.12 $3.37
Cost  per FIC/FIG
(vaccine
procurement
costs + delivery costs)
$2.58 $2.53 $11.93
Delivery cost per
FIC/FIG (no vaccine
procurement costs)
$0.54 $0.37 $10.23
Economic costs
Cost per dose (vaccine
procurement
costs + delivery costs)
$6.02 $7.51 $11.73
Delivery cost per dose
(no vaccine
procurement costs)
$0.68 $0.54 $4.76
Cost  per FIC/FIG
(vaccine
procurement
costs + delivery costs)
$18.16 $22.69 $35.66
Delivery cost per $2.08 $1.62 $14.45
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differences between routine infant vaccine delivery and episodic
delivery via campaigns has also been analyzed and taken into
7 It should be noted that Rwanda introduced RotaTeq® vaccine. Another rotavirusFIC/FIG (no vaccine
procurement costs)
rade was smaller than the total infant cohort of boys and girls for
revnar® and RotaTeq®. The estimated cost of RotaTeq® procure-
ent was greater than that of Prevnar® due to its higher price per
ose.
Economic unit costs were also higher for Gardasil®. The cost
f delivering the vaccine per fully immunized girl was $14.45
hile costs per fully immunized child of delivering Prevnar®
nd RotaTeq® vaccines were $2.08 and $1.62, respectively. Eco-
omic unit costs with vaccine procurements were greater for
otaTeq® than Prevnar® due to RotaTeq®’s higher vaccine price.
owever unit costs of delivering RotaTeq® (without vaccine pro-
urement) were slightly lower than for Prevnar® since RotaTeq®
s administered orally, resulting in less waste management
osts.
. Discussion
The annual costs of delivering three new vaccines in Rwanda
iffered due to vaccine presentations, vaccine prices, and prior
xistence of health system for vaccine delivery or need to create
ew service delivery system for a new target population. Two  of
he vaccines, Prevnar® and RotaTeq®, are more easily integrated
nto the existing immunization program since these were targeted
o children under one year old and delivered at health facilities
hile Gardasil® is targeted to an older age group and delivered in
chools. The ﬁnancial cost differences of introducing Prevnar® and
otaTeq® were small and could be attributed to vaccine presenta-
ion (also waste management requirements) while the variation
n economic costs were more substantial due to a higher cost
® ®er dose for RotaTeq than Prevnar . Governments that are Gavi-
ligible will have similar ﬁnancial costs when introducing Prevnar®
nd RotaTeq® due to the same co-ﬁnancing fees for procurement.
owever, if a government were not Gavi-eligible and were paying (2015) 7357–7363
to procure the two vaccines,7 there could be more signiﬁcant dif-
ferences in the cost of procuring the two vaccines.
The main ﬁnancial cost differences between Gardasil® and the
other two  vaccines were due to delivery costs related to reaching
a new target population and the reliance on delivering vaccines in
schools. For Prevnar® and RotaTeq®, the largest share of ﬁnancial
non-vaccine costs was  for supervision and monitoring and eval-
uation, while for Gardasil, it was  for service delivery. The largest
share of economic non-vaccine costs was service delivery for all
three vaccines.
The largest economic cost component for all three vaccines
was vaccines and injection supplies as was found in other studies
[1–3]. However, the economic cost for vaccines and injection sup-
plies was lower for Gardasil® since its target population includes
only girls and was smaller than the infant cohort. The largest non-
vaccine recurrent economic cost component was  service delivery,
which included transport, as found in other studies [1,2]. Another
study [3] has found that cold chain expansion was the largest cap-
ital/startup costs and that startup costs accounted for the largest
share of HPV vaccination costs [5]. This ﬁnding was similar to our
ﬁndings that the largest non-annualized capital/startup cost for
Rotateq® was cold chain. On the other hand, social mobilization was
the largest capital/startup cost for the other two  vaccines, Prevnar®
and Gardasil® as in the study by Quentin and colleagues [1].
The main difference between the ﬁnancial and economic cost
analyses for startup costs is the inclusion of health personnel time;
a substantial amount of health personnel time is involved in the
startup costs of training, sensitization and service delivery in the
introduction of Gardasil®. In planning for introduction of new vac-
cines, these personnel time costs need to be considered and taken
into account since there is an opportunity cost to the health person-
nel time. Social mobilization and IEC activities are also particularly
important to inform the population about the beneﬁts of vacci-
nation and how the vaccine will be delivered. Governments need
to plan ahead for these operational costs since these will need to
be ﬁnanced adequately. Donors such as Gavi only partially ﬁnance
the vaccine and do not fully support ongoing operational delivery
costs. In addition, such advance planning allows human resources
to be appropriately allocated and for the program to be successfully
implemented.
The delivery strategy is particularly important to consider since
delivery to a new target population that is currently without reg-
ular health services and which will be vaccinated outside health
facilities requires more resources. Delivering Gardasil® was more
costly since unlike new infant vaccines, delivery of Gardasil® was
unable to piggy back on an existing routine immunization delivery
infrastructure for the target population [15]. Instead, introduction
of HPV vaccine required creation of a new routine vaccine deliv-
ery service for a new target population. The target population of
9–13 year old children usually receives limited or no routine pre-
ventive or other health services so there is limited or no existing
preventive health service delivery system in place on which HPV
vaccine delivery can depend. Delivering HPV vaccine three times
within 6 months at schools in Rwanda required additional social
mobilization and IEC, transport and per diems as well as additional
health personnel time. Examination of the programmatic and costvaccine, Rotarix® vaccine, has a 2 dose schedule (instead of RotaTeq’s 3-dose sched-
ule) and the 2012 Rotarix® cost per dose is more similar to Prevnar® If one were
to compare costs of introducing Rotarix, the costs would be lower than those of
introducing Prevnar® .
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onsideration for development of the Gavi introduction grant for
PV vaccines.
After the introduction year, some synergies were achieved
hrough combining Gardasil® vaccination with delivery of other
nterventions and these could potentially be used to lower delivery
osts. For example, HPV vaccination of girls was  combined with
elivery of deworming medication for delivery of one Gardasil®
accine dose, thereby reducing the total amount of health person-
el time required for this activity. In addition, Gardasil® vaccination
or one dose in 2013 was combined with campaign delivery of
easles-rubella vaccination; this reduced the costs of transporta-
ion and the total time spent by health personnel on these two
mmunization activities.
Limitations to this analysis should be noted which may  have
ffected the accuracy of our cost estimations. Assumptions were
ade in the estimation of health personnel time spent on social
obilization and vaccination. Since the year of introduction in
wanda for the three vaccines varied, mixed methods using pri-
ary and secondary data sources with both prospective and
etrospective data collection had to be used. Due to lack of
nformation, some service delivery costs such as cold chain main-
enance and fuel at the district and health facility level, and
nergy to run the cold chain were missing. Thus, total costs of
elivering the vaccines were underestimated. In addition, not
ncluding the shared health systems costs across the three vac-
ines such as shared personnel and cold chain rooms may  have
esulted in lower estimates. Another limitation of the analysis is
hat some district/health facility level costs were not included.
astly, in this cost analysis, half of the actual cold chain costs
or Prevnar® was attributed to Gardasil®, since by 2012 when
ardasil® was introduced, Rwanda had switched the pneumococ-
al vaccine it was using to a smaller vaccine product presentation;
owever, this analysis approach meant that the Prevnar® intro-
uction costs were underestimated by 50% of the cold chain
osts.
This analysis provides useful information for the Rwandan gov-
rnment to determine its ﬁnancial outlays for new vaccines as well
s opportunity costs for its personnel. It also provides important
essons for countries that are not Gavi-eligible or are graduating
rom Gavi support since it provides estimates of the economic costs
hat the government will have to pay for expenses such as vaccine
rocurement and cold chain equipment costs. A government will
eed to consider its ability to pay for these vaccines and for delivery
osts, as such expenses have an impact on the sustainability of an
mmunization programme.
[
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